Insider Trading March 4, 2026

Artivion CCO Sells Shares to Meet Tax Withholding After PSU Vesting; Company Posts Strong Q4 Results

John E. Davis sold 4,573 shares to cover tax obligations tied to performance stock units as Artivion reports better-than-expected earnings and solid revenue growth

By Nina Shah AORT
Artivion CCO Sells Shares to Meet Tax Withholding After PSU Vesting; Company Posts Strong Q4 Results
AORT

Artivion Inc. Chief Commercial Officer John E. Davis sold 4,573 shares on March 3, 2026 to satisfy tax withholding tied to vested performance stock units, while receiving 28,845 shares on March 2, 2026 from the same award. The transactions leave Davis with 230,794 shares. The insider activity comes as the stock trades at $38.50, after a year-to-date rise of 54% and a 7.6% gain in the past week. Separately, Artivion reported fourth-quarter 2025 results that beat EPS expectations and delivered adjusted revenue growth of 18.5% year over year on a constant currency basis. An analysis cited in company data flags the stock as overvalued relative to its Fair Value estimate. The company is valued at $1.84 billion and maintains a "GOOD" financial health score.

Key Points

  • CCO John E. Davis sold 4,573 shares on March 3, 2026 at $37.7756 per share to cover tax withholding from vested PSUs; proceeds totaled $172,747.
  • Davis received 28,845 shares on March 2, 2026 as part of performance stock units granted on February 28, 2025 and now directly owns 230,794 shares.
  • Artivion reported Q4 2025 EPS of $0.17 versus a $0.06 forecast and adjusted revenues of $118.3 million, up 18.5% year over year on a constant currency basis - relevant to the medical device and broader healthcare sectors.

Transaction details

Artivion, Inc. (NASDAQ: AORT) disclosed that Chief Commercial Officer John E. Davis sold 4,573 shares of the company's common stock on March 3, 2026, at a sale price of $37.7756 per share, for total proceeds of $172,747. The Form 4 filing submitted to the Securities and Exchange Commission states that the disposition was made to cover tax withholding obligations associated with the vesting of performance stock units.

According to the same filing, Davis acquired 28,845 shares of common stock on March 2, 2026. Those shares were issued as part of performance stock units that had been granted on February 28, 2025. After these transactions were completed, Davis directly owned 230,794 shares of Artivion common stock.

Market context and valuation snapshot

The insider sale occurred while Artivion shares were trading at $38.50. The stock has risen 54% over the past year and gained 7.6% in the most recent week. An analysis noted in company information indicates the stock appears overvalued relative to its Fair Value estimate and is listed among names classified as Most Overvalued.

Artivion is valued at $1.84 billion and carries a "GOOD" financial health score in the referenced analysis. The company is reported to be profitable over the last twelve months, with net income expected to increase this year.

Recent operating performance

In other corporate disclosures, Artivion reported fourth-quarter 2025 results that outperformed consensus on earnings. The company posted earnings per share of $0.17, ahead of the forecasted $0.06. On revenue, Artivion recorded adjusted revenues of $118.3 million for the quarter, representing 18.5% year-over-year growth on a constant currency basis.

That adjusted revenue figure exceeded both Canaccord Genuity's internal estimate of $115.6 million and the consensus expectation of $116.5 million. Following the results, Canaccord Genuity revised its price target for Artivion to $48.00 from $51.00 but maintained a Buy rating. The firm attributed the adjustment to compressed multiples in comparable groups amid a recent stock market sell-off.

Contextual note

The insider sale was disclosed as a tax-related disposition connected to PSU vesting, while the PSU issuance was recognized in early March 2026 for a grant originally dated February 28, 2025. The company-level metrics and analyst action referenced above provide the backdrop for the insider transaction and current share-price movement.


Disclosure:

Risks

  • Valuation risk - the stock was identified as appearing overvalued relative to its Fair Value estimate, which may impact investor expectations in the capital markets.
  • Market volatility - Canaccord Genuity cited compressed multiples in comparable groups amid a recent stock market sell-off as the reason for lowering its price target, indicating sensitivity to market conditions.
  • Revenue and earnings sensitivity - while the company beat EPS expectations, revenue outcomes and analyst revisions can influence investor sentiment in the healthcare and medical device sectors.

More from Insider Trading

Q2 Holdings CPO Executes $1.18M Share Sale to Cover Tax Withholding Mar 4, 2026 Adaptive Biotechnologies CSO Executes $392,329 Sale of ADPT Shares Under 10b5-1 Plan Mar 4, 2026 Zevia Director Disposes of 40,000 Class A Shares in $57,516 Transaction Mar 4, 2026 AH Realty Trust Director Acquires 10,000 Shares; Armada Hoffler Posts Mixed Q4 Results Mar 4, 2026 Xencor CEO Dahiyat Sells $80K in Stock as Company Navigates Royalty Dispute and Pipeline Milestones Mar 4, 2026